Skip to main content
OpenTrials
Completed

NCT Number: NCT06381895

The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer

The aim of this study was to develop an radiomic model based on CT images to evaluate markers of the bladder cancer microenvironment, such as TSR,TIL, and IP. Secondly, the association of the radiomic model with clinical outcomes and immunotherapy response was investigated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bladder Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Immunotherapy Male Urogenital Diseases Neoplasms Neoplasms by Site Radiomics Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sun Yat-sen Memorial Hospital

Guangzhou, Guangdong, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age;
  • Performing TURB-t or RC during 2010-2022;
  • The primary lesion was located in the bladder, and the pathological diagnosis was urothelial carcinoma;
  • Complete clinical information, pathological data, preoperative pelvic enhanced CT and follow-up records;

Exclusion criteria

  • Patients with distant metastasis;
  • Combined with other malignant tumors or malignant tumor treatment history
  • Malignant tumors of upper urinary tract;
  • Clinical information, pathological data, preoperative pelvic enhanced CT and follow-up records were missing;
  • Other situations in which the researcher considers it inappropriate to participate in this study.

Treatment and study plan

Primary outcomes

  1. Tumour-infiltrating lymphocytes (TIL)

    Time frame: 1 year

    TILs were evaluated using paraffin-embedded tumour tissue samples stained with H&E according to established protocols.

Secondary outcomes

  1. overall survival

    Time frame: 1 year

    We obtain this data through telephone follow-up and evaluate it according to the date of surgery

  2. cancer-specific survival

    Time frame: 1 year

    We obtain this data through telephone follow-up and evaluate it according to the date of surgery

Sponsors and collaborators

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 24, 2024
Registry last updated
Apr 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.